{"id":"https://openalex.org/W2256115296","doi":null,"title":"Studier av lipolyse i humane myotuber fra normalvektige, fedme og fedme med type 2-diabetes","display_name":"Studier av lipolyse i humane myotuber fra normalvektige, fedme og fedme med type 2-diabetes","publication_year":2012,"publication_date":"2012-01-01","ids":{"openalex":"https://openalex.org/W2256115296","mag":"2256115296"},"language":"no","primary_location":{"id":"pmh:oai:www.duo.uio.no:10852/12066","doi":null,"is_oa":false,"landing_page_url":"http://urn.nb.no/URN:NBN:no-31684","pdf_url":null,"source":{"id":"https://openalex.org/S4306401716","display_name":"Duo Research Archive (University of Oslo)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I184942183","host_organization_name":"University of Oslo","host_organization_lineage":["https://openalex.org/I184942183"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Master thesis"},"volume":null,"type":"dissertation","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5049171382","display_name":"Shabana Alim","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Shabana Alim","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5049171382"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11844","display_name":"Lipid metabolism and biosynthesis","score":0.6265000104904175,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11844","display_name":"Lipid metabolism and biosynthesis","score":0.6265000104904175,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11339","display_name":"Metabolism, Diabetes, and Cancer","score":0.1216999962925911,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11457","display_name":"Adipose Tissue and Metabolism","score":0.11620000004768372,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lipolysis","display_name":"lipolysis","score":0.8579999804496765},{"id":"https://openalex.org/keywords/intramyocellular-triglyceride","display_name":"intramyocellular triglyceride","score":0.9290000200271606},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.7580000162124634},{"id":"https://openalex.org/keywords/obesity","display_name":"obesity","score":0.9649999737739563},{"id":"https://openalex.org/keywords/human-myotubes","display_name":"human myotubes","score":0.6460000276565552},{"id":"https://openalex.org/keywords/fatty-acid-uptake","display_name":"fatty acid uptake","score":0.8700000047683716},{"id":"https://openalex.org/keywords/hormone-sensitive-lipase","display_name":"hormone-sensitive lipase","score":0.8159999847412109},{"id":"https://openalex.org/keywords/adipose-triglyceride-lipase","display_name":"adipose triglyceride lipase","score":0.953000009059906},{"id":"https://openalex.org/keywords/diacylglycerol","display_name":"diacylglycerol","score":0.8510000109672546},{"id":"https://openalex.org/keywords/ceramide","display_name":"ceramide","score":0.8640000224113464},{"id":"https://openalex.org/keywords/insulin-resistance","display_name":"insulin resistance","score":0.5509999990463257},{"id":"https://openalex.org/keywords/triacylglycerol-biosynthesis","display_name":"triglyceride synthesis","score":0.6069999933242798},{"id":"https://openalex.org/keywords/glycerol-uptake","display_name":"glycerol uptake","score":0.6110000014305115},{"id":"https://openalex.org/keywords/fatty-acid-oxidation","display_name":"fatty acid oxidation","score":0.45500001311302185}],"concepts":[{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.5443475246429443},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.42036765813827515},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.23445406556129456},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.1773451268672943}],"mesh":[],"locations_count":2,"locations":[{"id":"pmh:oai:www.duo.uio.no:10852/12066","doi":null,"is_oa":false,"landing_page_url":"http://urn.nb.no/URN:NBN:no-31684","pdf_url":null,"source":{"id":"https://openalex.org/S4306401716","display_name":"Duo Research Archive (University of Oslo)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I184942183","host_organization_name":"University of Oslo","host_organization_lineage":["https://openalex.org/I184942183"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Master thesis"},{"id":"mag:2256115296","doi":null,"is_oa":false,"landing_page_url":"https://www.duo.uio.no/handle/10852/12066","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9763000011444092,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2046529037","https://openalex.org/W1988825731","https://openalex.org/W2985421729","https://openalex.org/W2136481623","https://openalex.org/W2462361061","https://openalex.org/W2474400559","https://openalex.org/W1999467000","https://openalex.org/W2555485352","https://openalex.org/W6990850982","https://openalex.org/W2057775672"],"abstract_inverted_index":{"Innledning:":[0],"Insulinresistens":[1],"og":[2,17,30,68,83,99,103,115,150,177,197,208,225,235,251,315,323],"type":[3,238,254],"2-diabetes":[4,255],"er":[5],"assosiert":[6],"med":[7,85,126,145,154,222,233,237,253,258,321,325,328],"akkumulering":[8,27],"av":[9,22,28,62,70,101,121,168,181,193,272,287,313],"intramyocellul\u00e6re":[10],"triglyserider":[11],"(IMTG),":[12],"lipid-intermediater":[13],"som":[14,34,45,51,242,265],"diacylglycerol":[15],"(DAG)":[16],"ceramider.":[18,31],"En":[19],"lavere":[20],"turnover":[21],"IMTG":[23,53,65,73],"vil":[24],"kunne":[25],"\u00f8ke":[26],"DAG":[29],"Fettsyrer":[32],"(FFA)":[33],"blir":[35,40],"tatt":[36],"opp":[37],"i":[38,59,76,133,142,172,183,212,218,282,290,294,299,309],"muskelceller":[39],"enten":[41],"oksidert":[42],"eller":[43,130,155,263,292],"lagret":[44],"IMTG.":[46],"Vi":[47,89],"ville":[48,90],"studere":[49],"prosesser":[50],"regulerer":[52],"turnover;":[54],"dvs.":[55],"oljesyre":[56,102,128,182,224],"(OA)":[57,129],"opptak":[58,98,176],"cellene,":[60],"frigj\u00f8ring":[61],"OA":[63,71],"fra":[64,78,112,185,229,249,319],"lager":[66,74],"(lipolyse)":[67],"gjenvinning":[69],"til":[72,267],"(reforestring)":[75],"myotuber":[77,111,184,228,318],"normalvektige":[79,186],"(NV),":[80],"fedme":[81,84,234,236,250,252,322,324],"(F)":[82],"T2D":[86,326],"(F+T2D)":[87],"individer.":[88],"ogs\u00e5":[91],"unders\u00f8ke":[92],"hvordan":[93],"ulike":[94,146],"farmakologiske":[95,147],"stoffer":[96],"p\u00e5virket":[97],"lipolyse":[100,151,220,291,316],"glyserol.\\n\\nMetode:":[104],"Fors\u00f8kene":[105],"ble":[106,123,139,152,164,202,243],"utf\u00f8rt":[107,166],"p\u00e5":[108,174,246],"differensierte":[109],"humane":[110],"NV,":[113],"F":[114],"F+T2D":[116],"donorer.":[117,187],"P\u00e5":[118,136],"dag":[119,137],"6":[120],"differensieringsperioden":[122],"myotubene":[124,248,283],"forbehandlet":[125],"radioaktiv":[127,131],"glyserol":[132,226],"24":[134],"timer.":[135],"7":[138],"cellene":[140],"behandlet":[141],"3":[143],"timer":[144],"stoffer.":[148],"Opptak":[149],"m\u00e5lt":[153,221],"uten":[156],"triacsin":[157],"C":[158],"tilstedet.":[159],"I":[160],"et":[161],"annet":[162],"fors\u00f8k":[163],"det":[165,203],"dose-respons":[167,206],"lipolysehemmere":[169],"(HSL+ATGL":[170],"hemmere":[171],"kombinasjon)":[173],"lipolyse,":[175],"ufullstendig":[178],"oksidasjon":[179],"(ASM)":[180],"For":[188],"\u00e5":[189,306],"finne":[190],"optimale":[191],"konsentrasjoner":[192],"hormon-sensitiv":[194],"lipase":[195,200],"(HSL)":[196],"fettvev":[198],"triglyserid":[199],"(ATGL)":[201],"innledningsvis":[204],"gjennomf\u00f8rt":[205],"fors\u00f8k.\\n\\nResultater":[207],"diskusjon:":[209],"Resultatene":[210],"presentert":[211,244],"denne":[213],"oppgaven":[214],"viste":[215],"klare":[216],"forskjeller":[217],"opptak,":[219],"b\u00e5de":[223],"hos":[227,296,317],"de":[230,269,276,297,310],"to":[231],"gruppene":[232],"2-diabetes.":[239],"De":[240],"forskjellene":[241,281],"tyder":[245],"at":[247,268],"donorgruppene":[256],"b\u00e6rer":[257],"seg":[259],"en":[260,288],"endring,":[261],"epigenetisk":[262],"genetisk,":[264],"f\u00f8rer":[266],"bevarer":[270],"noen":[271],"in":[273,278],"vivo-egenskapene":[274],"n\u00e5r":[275],"dyrkes":[277],"vitro.":[279],"Disse":[280],"kan":[284],"v\u00e6re":[285],"for\u00e5rsaket":[286],"dysfunksjon":[289],"defekt":[293],"fettsyreopptaket":[295],"enkelte":[298],"donorgruppene.":[300],"Det":[301],"trenges":[302],"flere":[303],"studier":[304],"for":[305],"f\u00e5":[307],"innsikt":[308],"mulige":[311],"endringer":[312],"fettsyreopptak":[314],"individer":[320],"sml.":[327],"NV":[329],"celler.":[330]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}